H.R. 7032
Referred to CommitteeIncreasing Transparency in Generic Drug Applications Act of 2022
Introduced 3/9/2022•117th Congress•House
Latest Action
Referred to the Subcommittee on Health.
3/10/2022 • House
Summary
Increasing Transparency in Generic Drug Applications Act of 2022
This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
Introduced in House • 3/9/2022
Enter your district to see how this bill affects your community
Topics & Subjects
Policy Area: Health
Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationPrescription drugs
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (2)
Party Breakdown
2
Democrats
0
Republicans
0
Independents
Sponsor
R[
Cosponsors (1)
R[
Bill Journey
Originated in the House
Introduced
March 9, 2022
Referred to the House Committee on Energy and Commerce.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (1)
Introduced in House3/9/2022